NextVivo, founded with the mission to revolutionize drug development, focuses on creating immune organoid technology. This biotech company aims to accelerate the development of safer and more effective therapies by generating and testing them in immune-competent human-derived models. Their core product, 3D holistic organoid models, replicates healthy and diseased tissues while retaining key immune cell types and their interactions, providing a more accurate platform for drug testing and development.

Notable figures associated with NextVivo include leading scientists and biotech investors who support its innovative approach. The company has achieved significant milestones in developing its organoid technology, which has the potential to transform preclinical drug testing by offering more reliable human-like models. This advancement not only promises to improve the efficacy and safety of new therapies but also aims to reduce the reliance on animal testing, thus making a substantial impact on the pharmaceutical industry.